China compatriots Xgene Pharmaceutical and Neurogen Pharma announced an exclusive licensing agreement on 15 July for XG005, a novel non-opioid oral analgesic targeting both inflammatory and neuropathic pain through dual COX inhibition and calcium channel modulation. Under the deal, Xgene will receive upfront payments, milestones and tiered royalties while Neurogen gains development and commercialisation rights in mainland China, Hong Kong and Macau.

XG005 demonstrated significant efficacy in US Phase II/III trials for bunionectomy pain and Chinese Phase IIb osteoarthritis studies, with 43% of surgical patients requiring no rescue medication. The drug is preparing for US Phase III abdominal surgery trials ahead of a new drug application (NDA) submission. Global pain management markets are projected to reach USD 107.5 billion by 2030, with non-opioid therapies addressing critical safety needs amid opioid abuse concerns.